Spontaneous coronary artery dissection (SCAD) is a non-atherosclerotic form of coronary artery disease of unknown cause that predominantly affects women (>90%; mean age 44-55 years) and can be fatal. The finding of familial clustering, including the concordant involvement of monozygotic twins, and its association with the PHACTR1/EDN1 genetic locus, indicate a genetic predisposition to its pathophysiology. A human induced pluripotent stem cell line (hiPSC) was generated from a patient who had survived an episode of SCAD. This disease-specific hiPSC line will be useful for the study of SCAD after differentiation into blood vessel-forming cells.
Resource utility
SCAD is a vasculopathy of unknown cause. However, consistent with a genetic predisposition, we recently showed highly significant association between SCAD and the rs9349379 A-allele of the PHACTR1/EDN1 genetic locus (odds ratio: 1.67, p < 1.67 × 10 −21 ) (Adlam et al., 2019) . To aid in understanding the pathophysiological mechanisms of SCAD, hiPSCs were generated from a SCAD survivor.
Resource details
SCAD is a non-atherosclerotic form of CAD that predominantly affects young to middle-aged women, accounting for 23-36% of acute myocardial infarcts, who have few traditional cardiovascular risk factors, such as obesity, diabetes, dyslipidemia or high blood pressure, and can recur in up to 30% of cases (Graham et al., 2018; Saw et al., 2017 
T
It is likely a systemic vasculopathy, associated not infrequently with other vascular disorders (fibromuscular dysplasia, cervical artery dissection, migraine), but evidence of inflammatory processes is lacking and associated genetic causes of vasculopathy, such as Ehlers Danlos and Loeys-Dietz, are rarely found. The rs9349379 A-allele of the PHACTR1/EDN1 genetic locus is strongly associated with SCAD, and a lower incidence of atherosclerotic coronary artery disease (AsCAD) (Adlam et al., 2019) , whereas the rs9349379 G-allele is associated with AsCAD and hypertension (Gupta et al., 2017) . SCAD causes myocardial ischemia or infarction due to the development of an intramural (Viswanathan et al., 2018) . Ten clones were generated. VCCRIi001-A showed typical human embryonic stem cell-like morphology (Fig. 1A) , expressed the pluripotent marker, OCT-4, by immunofluorescence ( Fig. 1B) and maintained 99.0% Tra-1-60 positivity by flow cytometry (Fig. 1C) . VCCRIi001-A also expressed high POU5F1, NANOG and SOX2 levels by qRT-PCR ( Fig. 1D, clone 7) , retained the rs9349379-AG variant (Fig. 1E ), differentiated into all three germ layers (ectoderm: PAX6, mesoderm: GATA4, endoderm: SOX17, Fig. 1F ), and was karyotypically normal (Fig. 1G ). Identity was verified by short tandem repeat (STR) analysis and the cells were mycoplasma negative. After repeated passaging, Sendai virus was eliminated from the hiPSCs (Fig. 1H) , making them foot-print free.
Materials and methods

Ethics statement
The generation and use of hiPSC were approved by the St Vincent's Hospital Human Research Ethics Committee (HREC/16/SVH/338); SVH File number: 16/245. All studies were performed according to approved guidelines after obtaining informed consent.
PBMCs collection and reprogramming
Blood (5 ml) was collected into an EDTA Vacutainer blood collection tube. PBMCs were isolated using a Ficoll (GE Healthcare) density gradient and cultured in StemSpan II medium with Erythroid expansion supplement (Stemcell Technologies). Reprogramming was performed using the Cytotunes 2.0 Kit (Thermo Fisher Scientific), as per manufacturer's instructions. Colonies exhibiting hiPSC-like morphology were manually selected 3-4 weeks post-transduction and maintained on Matrigel and mTeSR1™ plus (StemCell Technologies) with a 7-day passage cycle as described previously (Viswanathan et al., 2018) .
In vitro differentiation assay
Cells were differentiated in vitro into the three germ layers using STEMdiff Trilineage Differentiation kit (StemCell Technologies) as per manufacturer's instructions, fixed and stained for germ layer markers.
Immunofluorescence assay and flow cytometry
Cells were fixed with 4% paraformaldehyde (15 min, room temperature). For permeabilization and blocking, fixed cells were incubated for 30 min with PBS containing 10% donkey serum (Sigma) and 0.2% Triton X-100 (Sigma). Primary (overnight incubation, 4°C) and secondary (1 h, room temperature) antibodies were used as detailed in Table 1 . Samples were mounted with Prolong Gold antifade containing DAPI (Thermo Fisher Scientific) and images were captured by Zeiss LSM 700 confocal microscopy. For flow cytometry, cells were fixed in 4% paraformaldehyde (15 min, room temperature), blocked with PBS with 2% FBS for 30 min, incubated with primary (overnight, 4°C
) and secondary (1 h, room temperature) antibodies and run on Canto II (BD). A total of 10,000 events were acquired.
qRT-PCR
RNA was isolated using RNeasy Plus Mini kit (Qiagen). cDNA was generated using Superscript IV Vilo (Invitrogen) and amplified with SYBR Green Master mix on a LightCycler 480 II thermal cycler (Roche) under the following conditions: denaturation (95°C, 5 min), amplification (95°C, 15 s; 60°C, 30 s; 72°C, 30 s for 35 cycles) and final extension (72°C, 5 min). Ct values were calculated, and values normalized to GAPDH as the reference gene.
Elimination of Sendai virus
Sendai virus (SeV) was amplified by PCR using cDNA (10uL, generated from 1 μg of hiPSC RNA) and AccuPrime SuperMix 1 (Thermo Fisher Scientific) under the following conditions: denaturation (95°C, 30 s), amplification (95°C, 30 s; 55°C, 30 s; 72°C, 30 s for 30 cycles). Primers used are listed in Table 2 . PCR products were analyzed using 2% agarose gel electrophoresis.
Karyotyping and mycoplasma detection
hiPSCs were karyotyped by G-banding metaphase analysis Mishra, et al. Stem Cell Research 41 (2019) 101584 (Queensland Diagnostics, Brisbane, Australia), and confirmed to be mycoplasma-negative using the MycoAlert Mycoplasma detection kit (Lonza Biosciences), as per manufacturer's instructions.
Sanger sequencing and STR analysis
Genomic DNA was isolated from the patient's buccal cells using Purelink Genomic DNA kit (Invitrogen), and subjected to sequence analysis (Garvan Molecular Genetics Facility, NSW, Australia) using DNASTAR software. For STR analysis, genomic DNA was extracted from hiPSCs using DNAEasy Kit (Qiagen) and evaluated by the Garvan Molecular Genetics Facility.
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